The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations (Q37177597)

18 August 2017

1 reference

title

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations (English)

1 reference

non-small-cell lung carcinoma

18 August 2017

1 reference

Gregory J Riely

1

1 reference

18 August 2017

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

60 Suppl 2

1 reference

18 August 2017

S19-22

1 reference

EGFR inhibitors: what have we learned from the treatment of lung cancer?

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970101-6

7 January 2021

10.1016/S0169-5002(08)70101-6

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18513580